Canterbury DHB

Context

Further Reading

  1. Butt NM, et al. (2017). Guideline for the investigation and management of eosinophilia. British Journal of Haematology. Vol 76, Issue 4. February 2017 (pages 553–572).
  2. Genovese G, et al. (2014). Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J Med 2014; 371:2477-2487.
  3. Mingchao X, et al. (2014). Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine volume 20, pages 1472–1478.
  4. Valent P (2009). Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorders. Blood Rev 23(4): 157-65.
  5. Arber DA, et al. (2016). The 2016 revision to the World Health Organisation of Myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391-405.
  6. Helbig G, et al. (2012). Chronic Eosinophilic Leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation. Am J Hematol. 87:643-5.

About this Canterbury DHB document (540681):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

August 2018

Next Review:

April 2021

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 540681